Thirteen years of experience with eslicarbazepine acetate in the United Kingdom and Republic of Ireland: A safety perspective

被引:3
|
作者
Guedes, Luis [1 ,4 ]
Vieira, Mariana [1 ]
Gama, Helena [1 ]
Magano, Daniel [1 ]
Fernandes, Maria [1 ]
Calero, Patricia [2 ]
Di Foggia, Valentina [3 ]
机构
[1] BIAL Portela & Ca SA, Sao Mamede Do Coronado, Portugal
[2] Labs Bial SA, Madrid, Spain
[3] Bial UK Pharm Ltd, Windsor, England
[4] A Av Siderurgia Nacl, P-4745455 Sao Mamede Do Coronado, Portugal
关键词
drug-related side effects and adverse reactions; eslicarbazepine acetate; post-marketing; product surveillance; PARTIAL-ONSET SEIZURES; STEADY-STATE; DOUBLE-BLIND; ADJUNCTIVE TREATMENT; PHASE-III; ADULTS; PHARMACOKINETICS; EFFICACY; OXCARBAZEPINE; TOLERABILITY;
D O I
10.1002/epd2.20146
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveEslicarbazepine acetate (ESL) is a once-daily oral antiseizure medication. Its safety and tolerability from clinical trials have been mostly confirmed by real-world data. The main purpose of this report is to provide an overview of the safety profile of ESL in the United Kingdom (UK) and Republic of Ireland (ROI).MethodsSafety data were obtained from the UK and ROI post-marketing sources (October 2009-April 2022) by the marketing authorization holder. All individual reports were included in the Argus Safety (TM) database. All adverse events (AEs) were coded using MedDRA (R) version 24.1. Only valid cases (meeting the minimum pharmacovigilance reporting requirements) were included.ResultsDuring 13 years of ESL marketing, with cumulative estimated exposure of 2 210 395 patients-years, 183 reports were received. A total of 402 AEs were reported for the 155 valid reports. The most common reported AEs (>= 6% of total reported), per system organ class (SOC), were: nervous system disorders (23.4%), injury, poisoning, and procedural complications (18.9%), general disorders and administration site conditions (12.9%), psychiatric disorders (12.7%) and gastrointestinal disorders (6.7%). The most frequently reported (>= 2% of total reported) AEs were: seizure (4.5%), hyponatremia (4.2%), dizziness (2.7%), rash, fatigue (2.5% each), and somnolence (2.0%). Twenty-six percent of events were classified as serious (including six fatal cases).SignificanceThe current analysis supports the known safety profile of ESL, as generally well-tolerated with most AEs being non-serious. The most common AEs were considered either expected according to the disease itself or to the reference safety information. ESL continues to be a relevant medication in the treatment of partial (focal-onset) epilepsy, as also confirmed by the 2022 NICE guidelines.
引用
收藏
页码:803 / 814
页数:12
相关论文
共 50 条
  • [31] Representations of women and men in popular chemistry textbooks in the United Kingdom and Republic of Ireland
    Murray, Claire
    Anderson, Yvonne
    Simms, Charlie H.
    Seery, Michael K.
    CHEMISTRY EDUCATION RESEARCH AND PRACTICE, 2022, 23 (02) : 373 - 384
  • [32] Libraries and Information Services in the United Kingdom and the Republic of Ireland 2005-2006
    Turner, Richard
    NEW LIBRARY WORLD, 2007, 108 (1-2) : 91 - +
  • [33] The effect of deprivation on cancer incidence and mortality rates in the United Kingdom and the Republic of Ireland
    O'Leary, Eamonn
    EUROPEAN JOURNAL OF CANCER CARE, 2015, 24 : 51 - 52
  • [34] UNDERGRADUATE OBSTETRICS AND GYNECOLOGY IN THE UNITED-KINGDOM AND THE REPUBLIC-OF-IRELAND, 1989
    BIGGS, JSG
    HARDEN, RM
    HOWIE, P
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1991, 98 (02): : 127 - 134
  • [35] Libraries and Information Services in the United Kingdom and the Republic of Ireland 2009-2010
    Freeman, Mike
    NEW LIBRARY WORLD, 2011, 112 (3-4)
  • [36] Watching the Directive: Sports rights and public culture in the United Kingdom and the Republic of Ireland
    Murphy, Ken
    White, Andy
    INTERNATIONAL JOURNAL OF MEDIA & CULTURAL POLITICS, 2007, 3 (03) : 253 - 269
  • [37] Congenital brachial palsy: incidence, causes, and outcome in the United Kingdom and Republic of Ireland
    Evans-Jones, G
    Kay, SPJ
    Weindling, AM
    Cranny, G
    Ward, A
    Bradshaw, A
    Hernon, C
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2003, 88 (03): : 185 - 189
  • [38] Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults
    Andermann, Eva
    Rosenfeld, William
    Penovich, Patricia
    Rogin, Joanne
    Cendes, Fernando
    Carreno, Mar
    Ramsay, R. Eugene
    Ben-Menachem, Elinor
    Gama, Helena
    Rocha, Francisco
    Soares-da-Silva, Patricio
    Tosiello, Robert
    Blum, David
    Grinnell, Todd
    EPILEPSY RESEARCH, 2021, 169
  • [39] Paediatric intensive care follow-up provision in the United Kingdom and Republic of Ireland
    Manning, Joseph C.
    Scholefield, Barnaby R.
    Popejoy, Emma
    Dodds, Elizabeth
    Latour, Jos M.
    NURSING IN CRITICAL CARE, 2021, 26 (02) : 128 - 134
  • [40] Directory of Medical and Health Care Libraries in the United Kingdom and Republic of Ireland - Wright,DJ
    Cole, JE
    SERIALS LIBRARIAN, 1995, 27 (01): : 103 - 104